Ranbaxy: Extraordinary income propels growth - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Ranbaxy: Extraordinary income propels growth

Apr 30, 2001

Ranbaxy Laboratories, the domestic pharma major declared 47% increase in net profits. This was more than proportionate in light of only 19% growth in topline for 1QFY02. It was propeled by Rs 233 m income from technology licensing to Bayer. Excluding this extraordinary income, net profit infact, recorded a negative growth of 13%. Operating margins also dipped by 100 basis points inspite of an impressive 30% growth in export sales.The dip in operating margins appears to be on account of lower realisations in anti-infective segments.

(Rs m) 1QFY01 1QFY02 % Change
Sales 3,756 4,457 18.7%
Other Income 260 166 -36.2%
Expenditure 3,318 3,981 20.0%
Operating Profit (EBDIT) 438 476 8.7%
Operating Profit Margin (%) 11.7% 10.7% -8.4%
Interest 168 133 -20.8%
Depreciation 124 128 3.2%
Profit before Tax 406 381 -6.2%
Extraordinary Income - 233 -
Tax 15 40 166.7%
Profit after Tax/(Loss) 391 574 46.8%
Net profit margin (%) 10.4% 12.9%  
No. of Shares (eoy) (m) 116 116  
Diluted Earnings per share* 13.5 19.8  
P/E (at current price) 37.5 25.6  
(*- annualised)      

Other Income dipped primarily as the company didnít book any income from its subsidiary, Vidyut Investments compared to Rs 160 m in the corresponding quarter last year.Though we expect the net effect of all subsidiaries/joint ventures to be positive for the full year, the figure is still in the red to the tune of Rs 25 m (approx.) for 1QFY02.

On the R &D front Ranbaxy is in the Phase II trial for BPH molecule whereas animal studies for asthma molecule are expected to start by the end of the first half of the current year. R & D expenses increased marginally in the first quarter (6%). Meanwhile the company has also developed once a day NDDS for ofloxacin, an anti-infective drug.

At the current market price of Rs 506, the stock is trading at a P/e multiple of 30 times its FY02E earnings. The future potential of the stock depends on what breakthrough the company is able to achieve through its R &D work (particularly NDDS in the near term) as also the performance of the company in grabbing a share of US generics market cake.

Equitymaster requests your view! Post a comment on "Ranbaxy: Extraordinary income propels growth ". Click here!


More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Apr 1, 2015 (Close)


  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks